Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02103205
Other study ID # LIME2014
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date June 2014
Est. completion date May 2024

Study information

Verified date May 2024
Source Umeå University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Breast milk is the gold standard of early infant nutrition and breastfed infants have advantages in several short and long term outcomes compared to those formula-fed. The first aim of this study is to evaluate the effect of adding bovine lactoferrin to infant formula. The general hypothesis is that bovine lactoferrin reduces some of the previously observed differences between formula-fed and breast-fed infants with regard to health and development. The main outcome studied is the effect on immune function. The second aim is to study the effects of lower iron concentration in infant formula and to test the hypothesis that iron can be lowered without negative effects on health and development. The main outcome studied here is iron status. Other outcomes in this trial are microbiota composition, metabolomics, growth, body composition and cognitive development. To test the lactoferrin hypothesis, formula-fed infants will be recruited and fed a low iron (2 mg/L) control formula, or the same formula supplemented with bovine lactoferrin. To test the iron hypothesis, a third group will be fed the same formula (no lactoferrin) with higher iron concentration (8 mg/L). Group allocation for all formula-fed infants will be double-blind randomized. Additionally, breast-fed infants will be recruited and used as a reference group (gold standard).


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 252
Est. completion date May 2024
Est. primary completion date May 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 4 Weeks to 8 Weeks
Eligibility Inclusion Criteria: Formula-fed healthy infants at 6 +/- 2 weeks of age with: - birth weight 2500-4500 g - gestational age at birth = 37 completed weeks - no chronic disease or neonatal diagnoses believed to affect any outcome - no given blood transfusions or iron supplements Exclusion Criteria: -

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Formula with low iron concentration (2 mg/L) supplemented with bovine lactoferrin

Formula with low iron concentration (2mg/L) without lactoferrin

Formula with normal iron concentration (8 mg/L) without lactoferrin


Locations

Country Name City State
Sweden Umeå University, Department of Clinical Sciences Umeå

Sponsors (3)

Lead Sponsor Collaborator
Umeå University Mead Johnson Nutrition, University of California

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Other Lactoferrin in breastmilk Analyzed from mothers to the control group of breast fed infants. At baseline, 4 and 6 months of age
Primary Incidence of infections Morbidity journal, Health questionnaire Up to 12 months of age
Primary Cytokine levels IL-2, TNF-alpha At 6 months of age
Primary Iron status s-ferritin, s-transferrin, s-iron, s-transferrin receptor concentration, reticulocyte Hb At 6 months of age
Secondary Dietary intake Dietary journal At baseline, 3, 4, 5, 6 and 12 months of age
Secondary Growth Anthropometric data, Body Composition (PeaPod) At baseline, 4, 6, 12 months of age and 6 years of age
Secondary Bloodpressure At baseline, 4, 6, 12 months of age and 6 years of age
Secondary Antibody response to vaccines s-levels of specific antibodies to vaccines (DTP, Hib, PC) At baseline, 4, 6 and 12 months of age
Secondary Gut microbiota Stool samples At baseline, 4, 6, 12 months of age and 6 years of age
Secondary Saliva proteins Saliva total protein content, lactoferrin, saliva-peroxidase, IgA and amylase At 4 months of age
Secondary Inflammatory markers s-hsCRP, s-calprotectin At baseline, 4, 6 and 12 months of age and 6 years age
Secondary Cognitive development and behavior Bayley III, Wechsler Intelligence Scale for Children (WISC), Behavioral questionnaire At 1 and 6 years of age
Secondary s-hepcidin At baseline, 4, 6, 12 months of age and 6 years of age
Secondary Metabolomics Analyzed in urine and serum samples At baseline, 4, 6, 12 months of age and 6 years of age
Secondary Amino acids p-amino acids At 4 and 6 months of age
Secondary Blood urea nitrogen p-urea nitrogen At 4 and 6 months of age
Secondary Cytokine levels IL-2 and TNF alpha at baseline, 4 and 12 months of age and 6 years of age. Six additional cytokines at baseline, 4, 6 and 12 months of age and 6 years of age. At baseline, 4, 6, 12 months of age and 6 years of age
Secondary Iron status s-ferritin, s-transferrin, s-iron, s-transferrin saturation, s-transferrin receptor concentration, retuiculocyte Hb At baseline, 4 and 12 months of age and 6 years of age